AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27564444 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) program during hearing aid fitting
Number of subjects: 50
Study 27564444 — intervention group
Group type: COMPARATOR
Intervention: Standard Practice (SP)
Number of subjects: 50
Study 25098218 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily
Number of subjects: 36
Study 25098218 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice daily
Number of subjects: 36
Study 25098218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 22503337 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo manipulation (open or hidden administrations of lidocaine)
Number of subjects: 19
Study 22503337 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo manipulation
Number of subjects: 19
Study 20683750 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal nerve block
Number of subjects: 120
Study 20683750 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia
Number of subjects: 120
Study 17992062 — intervention group
Group type: EXPERIMENTAL
Intervention: PABM-intervention (50 minutes of physical activity twice a week + 50 minutes of behavior modification once a week)
Number of subjects: 32
Study 17992062 — intervention group
Group type: COMPARATOR
Intervention: Behavior modification only intervention (50 minutes of instruction for modifying lifestyle habits once a week)
Number of subjects: 32
Study 15871112 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV acquisition in younger women
Number of subjects: 7237
Study 15871112 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV persistence in older women
Number of subjects: 7237
Study 15871112 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HPV trends
Number of subjects: 7237
Study 11885548 — intervention group
Group type: EXPERIMENTAL
Intervention: Full vegetable fat milk (FVF) (3.5 g fat/dL; 100% vegetable fat from palm-, coconut- and soybean oil)
Number of subjects: 37
Study 11885548 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially vegetable fat milk (PVF) (3.5 g fat/dL; 50% vegetable fat from rapeseed oil, 50% milk fat)
Number of subjects: 37
Study 11885548 — intervention group
Group type: COMPARATOR
Intervention: Standard-fat milk (SF) (3.5 g cow's milk fat/dL)
Number of subjects: 37
Study 11885548 — intervention group
Group type: COMPARATOR
Intervention: Low-fat milk (LF) (1.0 g cow's milk fat/dL)
Number of subjects: 37
Study 11725682 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntac Sprint/Tetric Ceram
Number of subjects: 33
Study 11725682 — intervention group
Group type: COMPARATOR
Intervention: Syntac Classic/Tetric
Number of subjects: 33
Study 7497825 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-denying feedback
Number of subjects: 0
Study 7497825 — intervention group
Group type: COMPARATOR
Intervention: Neutral feedback
Number of subjects: 0
Study 7497825 — intervention group
Group type: EXPERIMENTAL
Intervention: Misleading information about actions of the pediatrician and assistant
Number of subjects: 0
Study 7497825 — intervention group
Group type: COMPARATOR
Intervention: Nonmisleading information about actions of the pediatrician and assistant
Number of subjects: 0
Study 2197158 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (200 mg once daily)
Number of subjects: 30
Study 2197158 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (400 mg once daily)
Number of subjects: 30
Study 2197158 — intervention group
Group type: COMPARATOR
Intervention: Captopril (50 mg twice daily)
Number of subjects: 30
Study 6791204 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 200 mg per day for 1 week
Number of subjects: 8
Study 6791204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30346191 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress task condition
Number of subjects: 126
Study 30346191 — intervention group
Group type: COMPARATOR
Intervention: Neutral (reading) task condition
Number of subjects: 126
Study 29303128 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbuccal group (Group A) fixed with 7 mm long self‐tapping 2.0 mm titanium screws at 85° to the reference line
Number of subjects: 20
Study 29303128 — intervention group
Group type: COMPARATOR
Intervention: Transoral group (Group B) fixed with 7 mm long self‐tapping 2.0 mm titanium screws at 15° to the reference line
Number of subjects: 20
Study 26098427 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 and Folic Acid
Number of subjects: 422
Study 26098427 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 alone
Number of subjects: 422
Study 26098427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study 25638996 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutured extraction wound (Group A)
Number of subjects: 90
Study 25638996 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable gelatin sponges without suturing (Group B)
Number of subjects: 90
Study 25638996 — intervention group
Group type: COMPARATOR
Intervention: No gelatin sponge or suturing (Group C)
Number of subjects: 90
Study 23098014 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical simulation intervention group participating in two simulated pediatric palliative care scenarios
Number of subjects: 0
Study 23098014 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 19923506 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic lidocaine infusion
Number of subjects: 67
Study 19923506 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 67
Study 16897236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (6000 units x kg(‐1) infusion started 1 h after surgery)
Number of subjects: 30
Study 16897236 — intervention group
Group type: COMPARATOR
Intervention: Control (no protease inhibitors infused)
Number of subjects: 30
Study 13129862 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation treatment
Number of subjects: 214
Study 11075308 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) administered by dry-powder inhaler (DPI)
Number of subjects: 30
Study 11075308 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) administered by metered-dose inhaler with an alternate propellant (MDI-AP)
Number of subjects: 30
Study 11075308 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) administered by intravenous (i.v.) route
Number of subjects: 30
Study 11075308 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) administered by DPI (separate study with tritiated MF)
Number of subjects: 30
Study 8898422 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (flexible sigmoidoscopic screening)
Number of subjects: 799
Study 8898422 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 799
Study 8898422 — intervention group
Group type: COMPARATOR
Intervention: Non-attendees for screening examination
Number of subjects: 799
Study 1892032 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium sulfate (600-900 ml orally and 400 ml rectally)
Number of subjects: 10
Study 6308933 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximized metabolic control (group B)
Number of subjects: 0
Study 6308933 — intervention group
Group type: COMPARATOR
Intervention: Standard control (group A)
Number of subjects: 0
Study 30662004 — intervention group
Group type: EXPERIMENTAL
Intervention: Kefir (400 mL/day for 4 weeks)
Number of subjects: 45
Study 28797450 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tube feeding prior to treatment
Number of subjects: 125
Study 28797450 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 125
Study 25836351 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-month treatment with fluticasone and salmeterol (500/50 μg bid)
Number of subjects: 114
Study 25836351 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-month treatment with fluticasone (500 μg bid)
Number of subjects: 114
Study 23380979 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual rehabilitation
Number of subjects: 20
Study 23380979 — intervention group
Group type: COMPARATOR
Intervention: Magnifying visual aids (Control)
Number of subjects: 20
Study 21935686 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium administered at 0.7‐1.0 mg/kg for tracheal intubation, with repeated bolus administration (10 mg) or continuous infusion (15‐25 mg/h)
Number of subjects: 134
Study 18077189 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal irrigation (TI) using a 3.2mm arthroscope under local anaesthesia
Number of subjects: 150
Study 18077189 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection (CSI) of 40 mg triamcinolone acetonide and 1% lidocaine
Number of subjects: 150
Study 16595218 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone (LH) surge group
Number of subjects: 150
Study 16595218 — intervention group
Group type: COMPARATOR
Intervention: Follicle monitoring/human chorionic gonadotropin (hCG) group
Number of subjects: 150
Study 14973802 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extubation (2 hours after surgery)
Number of subjects: 60
Study 14973802 — intervention group
Group type: COMPARATOR
Intervention: Late extubation (6 hours after surgery)
Number of subjects: 60
Study 14973802 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received a bolus of ketobemidone and continuous infusion
Number of subjects: 60
Study 11212161 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg alendronate (ALN)
Number of subjects: 208
Study 11212161 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg alendronate (ALN)
Number of subjects: 208
Study 11212161 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5/10 mg alendronate (ALN)
Number of subjects: 208
Study 11212161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 11212161 — intervention group
Group type: EXPERIMENTAL
Intervention: Any dose of alendronate (ALN)
Number of subjects: 208
Study 11212161 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg and 10 mg alendronate (ALN)
Number of subjects: 208
Study 11212161 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN)
Number of subjects: 208
Study 9458995 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral and environmental interventions based on Piaget's cognitive developmental stages
Number of subjects: 0
Study 9458995 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 8172505 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional Intravenous Ismelin blocks
Number of subjects: 26
Study 8172505 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyl radical scavenger, dimethylsulfoxide (DMSO)
Number of subjects: 26
Study 8172505 — intervention group
Group type: COMPARATOR
Intervention: Control group (elective hand-surgery patients)
Number of subjects: 26
Study 8172505 — intervention group
Group type: EXPERIMENTAL
Intervention: Dystrophy patients
Number of subjects: 26
Study 2450479 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 11
Study 2450479 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 11
Study 30222120 — intervention group
Group type: EXPERIMENTAL
Intervention: BioMime sirolimus‐eluting stent (SES)
Number of subjects: 256
Study 30222120 — intervention group
Group type: COMPARATOR
Intervention: XIENCE everolimus‐eluting stent (EES)
Number of subjects: 256
Study 30222120 — intervention group
Group type: EXPERIMENTAL
Intervention: BioMime SES
Number of subjects: 256
Study 30222120 — intervention group
Group type: COMPARATOR
Intervention: XIENCE EES
Number of subjects: 256
Study 26279490 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath video laryngoscope
Number of subjects: 35
Study 25428566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy with wrist orthosis
Number of subjects: 60
Study 25428566 — intervention group
Group type: COMPARATOR
Intervention: Paraffin bath therapy with wrist orthosis
Number of subjects: 60
Study 23567980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (8 departments; N = 171 workers)
Number of subjects: 297
Study 23567980 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 departments; N = 122 workers)
Number of subjects: 297
Study 20736470 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective IABP insertion before PCI
Number of subjects: 301
Study 20736470 — intervention group
Group type: COMPARATOR
Intervention: No planned IABP
Number of subjects: 301
Study 19013107 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (25 mg/m²) plus gemcitabine (1000 mg/m²) followed by docetaxel (60 mg/m²)
Number of subjects: 401
Study 19013107 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (225 mg/m²) plus carboplatin (AUC=6)
Number of subjects: 401
Study 19013107 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine plus gemcitabine followed by docetaxel
Number of subjects: 401
Study 19013107 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus carboplatin
Number of subjects: 401
Study 16377253 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 37
Study 16377253 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 37
Study 12709263 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfactory BP control (group I)
Number of subjects: 229
Study 12709263 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled clinic BP (group II)
Number of subjects: 229
Study 12709263 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractory hypertension (group III)
Number of subjects: 229
Study 12709263 — intervention group
Group type: COMPARATOR
Intervention: Non-dipping status
Number of subjects: 229
Study 10846775 — intervention group
Group type: EXPERIMENTAL
Intervention: MCA PSV > 1 SD
Number of subjects: 196
Study 10846775 — intervention group
Group type: COMPARATOR
Intervention: MCA PSV
Number of subjects: 196
Study 9096989 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin, 20 mg daily, titrated up to 40 mg daily
Number of subjects: 202
Study 8253923 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 31338 [FSH/LH 3:1]
Number of subjects: 20
Study 8253923 — intervention group
Group type: COMPARATOR
Intervention: Metrodin (purified FSH)
Number of subjects: 20
Study 3330028 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release nifedipine 20 mg b.d.
Number of subjects: 94
Study 3330028 — intervention group
Group type: COMPARATOR
Intervention: Cyclopenthiazide 0.25 mg with 8.1 mmol potassium daily
Number of subjects: 94
Study 29092786 — intervention group
Group type: EXPERIMENTAL
Intervention: AR101
Number of subjects: 55
Study 29092786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 27175282 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 15
Study 27175282 — intervention group
Group type: COMPARATOR
Intervention: No-exercise (usual care) control group
Number of subjects: 15
Study 23825160 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonicare FlexCare electric brush with filled resin sealant (ProSeal)
Number of subjects: 118
Study 23825160 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual (elmex interX short head) plus interdental (Curaprox CPS 15) brush with filled resin sealant (ProSeal)
Number of subjects: 118
Study 23825160 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual brush only with filled resin sealant (ProSeal)
Number of subjects: 118
Study 23825160 — intervention group
Group type: COMPARATOR
Intervention: Manual brush only without sealant
Number of subjects: 118
Study 22682391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (8 sessions over a 4-week period)
Number of subjects: 80
Study 22682391 — intervention group
Group type: COMPARATOR
Intervention: Routine follow-up care (Control group)
Number of subjects: 80
Study 19545680 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordyceps sinensis (CS) 1.0 g 3 times a day
Number of subjects: 202
Study 19545680 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard immunosuppressive regimen)
Number of subjects: 202
Study 17304127 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral instrumentation (Group 1)
Number of subjects: 82
Study 17304127 — intervention group
Group type: COMPARATOR
Intervention: Unilateral instrumentation (Group 2)
Number of subjects: 82
Study 15087307 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogenated fat diet
Number of subjects: 8
Study 15087307 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fat diet
Number of subjects: 8
Study 15087307 — intervention group
Group type: COMPARATOR
Intervention: Unsaturated fat diet
Number of subjects: 8
Study 11579708 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (2 ng/kg/min for 5 consecutive days over 8 hours/day, then 8 hours on one day every 6 weeks)
Number of subjects: 46
Study 11579708 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (40 mg/day orally)
Number of subjects: 46
Study 9676145 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre-supplemented enteral formula (FSF)
Number of subjects: 16
Study 9676145 — intervention group
Group type: COMPARATOR
Intervention: Fibre-free formula (FFF)
Number of subjects: 16
Study 9676145 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 8087503 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2569322 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 17/582 (100 mg twice daily)
Number of subjects: 0
Study 2569322 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 2569322 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 2569322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 778306 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (600 mg/day in three divided doses)
Number of subjects: 15
Study 778306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 778306 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 15
Study 30496706 — intervention group
Group type: EXPERIMENTAL
Intervention: HYPO (hypohydration)
Number of subjects: 16
Study 30496706 — intervention group
Group type: COMPARATOR
Intervention: RE (rehydration)
Number of subjects: 16
Study 30496706 — intervention group
Group type: EXPERIMENTAL
Intervention: HYPO
Number of subjects: 16
Study 28877715 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Pirfenidone
Number of subjects: 0
Study 28877715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26194933 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated control of FiO2
Number of subjects: 27
Study 26194933 — intervention group
Group type: COMPARATOR
Intervention: Manual control of FiO2
Number of subjects: 27
Study 23440694 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG treatment
Number of subjects: 143
Study 23440694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-IVIG cytokine levels
Number of subjects: 143
Study 23440694 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-IVIG cytokine levels
Number of subjects: 143
Study 23440694 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 level >8 pg/ml (pre-IVIG)
Number of subjects: 143
Study 23440694 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFα level <2 pg/ml (pre-IVIG)
Number of subjects: 143
Study 23440694 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 level >10 pg/ml (post-IVIG)
Number of subjects: 143
Study 23440694 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 level >6 pg/ml (post-IVIG)
Number of subjects: 143
Study 21146468 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (NMDA receptor antagonist)
Number of subjects: 0
Study 21146468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19463081 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-supervised exercises in addition to conventional intervention
Number of subjects: 102
Study 19463081 — intervention group
Group type: COMPARATOR
Intervention: Conventional intervention (control group)
Number of subjects: 102
Study 19463081 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention
Number of subjects: 102
Study 19463081 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported recovery
Number of subjects: 102
Study 22297150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride (.5 mg/kg)
Number of subjects: 15
Study 22297150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15900286 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg gemfibrozil
Number of subjects: 12
Study 15900286 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg itraconazole
Number of subjects: 12
Study 15900286 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil and itraconazole combination
Number of subjects: 12
Study 15900286 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 12821221 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 72
Study 12821221 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72
Study 10535238 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-training program
Number of subjects: 238
Study 7594122 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus dietary intervention (n = 15)
Number of subjects: 32
Study 7594122 — intervention group
Group type: COMPARATOR
Intervention: Exercise only (n = 17)
Number of subjects: 32
Study 2187175 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized metaproterenol sulfate 5% inhalant solution at a dose of 0.01 mL/kg
Number of subjects: 30
Study 2187175 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized metaproterenol sulfate 5% inhalant solution at a dose of 0.02 mL/kg
Number of subjects: 30
Study 2187175 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 30
Study 7023676 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-day treatment with cephradine capsules, 500 mg BID
Number of subjects: 71
Study 7023676 — intervention group
Group type: COMPARATOR
Intervention: Ten-day treatment with cephradine capsules, 500 mg BID
Number of subjects: 71